ಪರಿಚಯ
ಜೀವರಸಾಯನಶಾಸ್ತ್ರ ವಿಭಾಗ
ಜೀವರಸಾಯನಶಾಸ್ತ್ರ ವಿಭಾಗವು ರೋಗಿಯ ಆರೈಕೆ, ಬೋಧನೆ ಮತ್ತು ಸಂಶೋಧನೆಗಳನ್ನು ಒಳಗೊಂಡಿರುವ ಒಂದು ಸಮಗ್ರ ವಿಭಾಗವಾಗಿದೆ. ರೋಗಿಯ ಆರೈಕೆಗಾಗಿ ವಿಶೇಷ ರಸಾಯನಶಾಸ್ತ್ರ ಪರೀಕ್ಷೆಗಳೊಂದಿಗೆ ಕ್ಯಾನ್ಸರ್‌ಗೆಡ್ಡೆಗಳ ಗುರುತುಹಚ್ಚುವಿಕೆ (ಮಾರ್ಕಿಂಗ್) ಸೇರಿದಂತೆ ದಿನನಿತ್ಯದ ವೈದ್ಯಕೀಯ ರಸಾಯನಶಾಸ್ತ್ರದ ತಪಾಸಣೆಗಳ ಸೇವಾ ಚಟುವಟಿಕೆಗಳನ್ನು ವಿಭಾಗದಲ್ಲಿ ನಡೆಸಲಾಗುತ್ತಿದೆ. ಸ್ಪೆಕ್ಟ್ರೋಫೊಟೊಮೆಟ್ರಿಕ್, ಕೆಮಿಲುಮಿನೆಸ್ಸೆನ್ಸ್ ಆಧಾರಿತ ಸ್ವಯಂ-ವಿಶ್ಲೇಷಕಗಳು, ಪಿಸಿಆರ್, ಆರ್‌ಟಿಪಿಸಿಆರ್ ಸಿಆರ್ ಮುಂತಾದ ಅತ್ಯಾಧುನಿಕ ಯಂತ್ರೋಪಕರಣಗಳು ವಾರ್ಷಿಕವಾಗಿ 10, 00,000 ತಪಾಸಣೆಗಳನ್ನು ಪೂರೈಸುತ್ತದೆ. ಗುಣಮಟ್ಟದ ವರದಿಗಳು ಬಿಡುಗಡೆಯಾಗುವುದನ್ನು ಖಚಿತಪಡಿಸಿಕೊಳ್ಳಲು, ನಿಯಮಿತ ಆಂತರಿಕ ಗುಣಮಟ್ಟದ ನಿಯಂತ್ರಣ ಮತ್ತು ಬಾಹ್ಯ ಗುಣಮಟ್ಟದ ನಿಯಂತ್ರಣ ಕಾರ್ಯಕ್ರಮಗಳನ್ನು ಕೈಗೊಳ್ಳಲಾಗುತ್ತಿದೆ.
ಶೈಕ್ಷಣಿಕ ಚಟುವಟಿಕೆಗಳು
ವಿಭಾಗವು ಹಲವಾರು ಬೋಧನಾ ಕಾರ್ಯಕ್ರಮಗಳಲ್ಲಿ ಸಕ್ರಿಯವಾಗಿ ತೊಡಗಿಸಿಕೊಂಡಿದೆ. ಬಿ.ಎಸ್ಸಿ.ಯಂತಹ ಒಗ್ಗೂಡಿದ ಆರೋಗ್ಯ ವಿಜ್ಞಾನಗಳ ಪದವಿಪೂರ್ವ ಕಾರ್ಯಕ್ರಮಗಳು, ಮೆಡಿಕಲ್ ಲ್ಯಾಬೊರೇಟರಿ ಟೆಕ್ನಾಲಜಿ ಕೋರ್ಸ್, ಪಿ.ಹೆಚ್‌ಡಿ. ಮುಂತಾದ ಸ್ನಾತಕೋತ್ತರ ಕಾರ್ಯಕ್ರಮಗಳು, ರಾಜೀವ್ ಗಾಂಧಿ ಆರೋಗ್ಯ ವಿಜ್ಞಾನಗಳ ವಿಶ್ವವಿದ್ಯಾಲಯಕ್ಕೆ (ಆರ್‌.ಜಿ.ಯು.ಹೆಚ್‌.ಎಸ್) ಸಂಯೋಜನೆಗೊಂಡಿದೆ. ಜೊತೆಗೆ, ತಮ್ಮ ಪ್ರೌಢಪ್ರಬಂಧದ ಕೆಲಸಕ್ಕಾಗಿ ಸ್ನಾತಕೋತ್ತರ ವೈದ್ಯಕೀಯ ಮತ್ತು ಡೆಂಟಲ್ ವಿದ್ಯಾರ್ಥಿಗಳಿಗೆ ಮಾರ್ಗದರ್ಶನ ಮತ್ತು ಸೌಲಭ್ಯಗಳನ್ನು ಒದಗಿಸಲಾಗುತ್ತಿದೆ. ಇತರ ವಿಶ್ವವಿದ್ಯಾಲಯಗಳಿಂದ ಪದವಿಪೂರ್ವ ಮತ್ತು ಸ್ನಾತಕೋತ್ತರ ಪದವಿ ಮತ್ತು ವೈದ್ಯಕೀಯೇತರ ವಿದ್ಯಾರ್ಥಿಗಳನ್ನು ನಿಯಮಿತವಾಗಿ ತರಬೇತಿ ಕಾರ್ಯಕ್ರಮಗಳಿಗೆ ನಿಯೋಜನೆ ಮೇರೆಗೆ ವಿಭಾಗಕ್ಕೆ ಬರುತ್ತಿದ್ದಾರೆ.
ಸಂಶೋಧನಾ ಚಟುವಟಿಕೆಗಳು
ಡಾಕ್ಟರೇಟ್ ಪದವಿಗಾಗಿ ಸಂಶೋಧನಾ ಕಾರ್ಯವನ್ನು ಕೈಗೊಳ್ಳಲು ರಾಜೀವ್ ಗಾಂಧಿ ಆರೋಗ್ಯ ವಿಜ್ಞಾನಗಳ ವಿಶ್ವವಿದ್ಯಾಲಯವು ಈ ವಿಭಾಗಕ್ಕೆ ಮಾನ್ಯತೆಯನ್ನು ನೀಡಿದೆ. ಹಲವಾರು ಸಂಶೋಧನಾ ಯೋಜನೆಗಳನ್ನು ಡಿಎಸ್ಟಿ, ಡಿಬಿಟಿ, ಐಸಿಎಂಆರ್ ಮತ್ತು ಆರ್‌.ಜಿ.ಯು.ಹೆಚ್‌.ಎಸ್. ಅಡಿಯಲ್ಲಿ ಮಂಜೂರು ಮಾಡಲಾಗಿದೆ. ಪ್ರಸ್ತುತ, ಐದು ಪಿ.ಹೆಚ್‌ಡಿ. ವಿದ್ಯಾರ್ಥಿಗಳು ನೋಂದಣಿಗೊಂಡು ಪ್ರೌಢಪ್ರಬಂಧದ ಕೆಲಸವನ್ನು ನಡೆಸುತ್ತಿದ್ದಾರೆ.
ಸೌಲಭ್ಯಗಳು
Details of available equipments in the department :
|
Cobas C311 Auoanalyser
|
Spectrophotometer
|
|
Cobas e411 Immuno Analyzer
|
Elisa Reader
|
|
Semi Autoanalyser Modulab – 5010
|
Centrifuges
|
|
Ion Selective Electrolyte Analyzer
|
Microcentrifuge
|
|
PCR conventional gradient (Thermal Cycler)
|
Drybath with cooling and mixing
|
|
PCR Real Time
|
Waterbath
|
|
Gel documentation system
|
Incubator
|
|
Electrophoresis unit
|
UV Transilluminator
|
|
Microwave oven
|
Vertex mixer
|
|
Ice maker
|
Freezers −20ºC, −80º C
|
Services provided in the Department
Routine Investigation : Routine blood test for biochemical parameters like, Blood sugar, RFT, LFT, LDH, Calcium, Uric acid, Cholesterol & Electrolytes like Sodium and Potassium
Special Investigation : Thyroid Function Test- T3,T4 & TSH, Thyroglobulin, Anti TG, Anti TPO
Tumor Markers : CEA, PSA, AFP, CA 125, BHCG, CA 19.9
Details of Seminars/ Conference/ Workshops/ Training programme conducted
Medical Education – Teaching and Learning(Lecture, Seminar, Symposium, CME, Conference etc) MCI/RGUHS criteria
1. Conduct classes for UG students as per the university guidelines.
2. Conduct journal club, seminars and scientific discussions for Ph.D students.
ಅಂಕಿಅಂಶಗಳು
|
Month
|
Glu
|
UREA
|
CREA
|
TP
|
ALB
|
ALP
|
BIL
|
AST
|
ALT
|
LDH
|
CAL
|
CHOL
|
UA
|
Na
|
K
|
D.BIL
|
Total |
|
Jan
|
6090 |
7252 |
7324 |
5973 |
6015 |
5966 |
5977 |
5982 |
5982 |
1088 |
2972 |
139 |
735 |
5474 |
5474 |
-
|
72443 |
|
Feb
|
5690 |
6938 |
7000 |
5682 |
5763 |
5685 |
5688 |
5691 |
5691 |
1024 |
2957 |
109 |
714 |
5206 |
5206 |
-
|
69044 |
|
Mar
|
6517 |
8043 |
8112 |
6595 |
6696 |
6596 |
6605 |
6611 |
6611 |
1040 |
3437 |
111 |
754 |
6085 |
6085 |
-
|
79898 |
|
Apr
|
5652 |
7537 |
7578 |
6132 |
6220 |
6138 |
6140 |
6147 |
6147 |
1096 |
3221 |
108 |
794 |
5691 |
5691 |
-
|
74592 |
|
May
|
6368 |
8156 |
8204 |
6505 |
6560 |
6504 |
6514 |
6517 |
6517 |
1132 |
3554 |
81 |
835 |
6208 |
6208 |
-
|
79863 |
|
Jun
|
5693 |
7577 |
7614 |
5992 |
6070 |
5994 |
5989 |
5999 |
5999 |
976 |
3172 |
78 |
693 |
5659 |
5659 |
-
|
73164 |
|
Jul
|
6802 |
8838 |
8894 |
7105 |
7212 |
7105 |
7105 |
7142 |
7142 |
1092 |
3798 |
79 |
641 |
6636 |
6636 |
-
|
86227 |
|
Aug
|
6802 |
7894 |
7940 |
6325 |
6397 |
6321 |
6332 |
6346 |
6346 |
991 |
3493 |
77 |
631 |
6070 |
6070 |
-
|
77315 |
|
Sep
|
5903 |
8038 |
8103 |
6284 |
6334 |
6273 |
6287 |
6296 |
6296 |
932 |
3213 |
84 |
629 |
6103 |
6103 |
-
|
76877 |
|
Oct
|
6441 |
8573 |
8667 |
6803 |
6881 |
6790 |
6796 |
6812 |
6812 |
866 |
3648 |
58 |
754 |
6727 |
6727 |
-
|
83355 |
|
Nov
|
6769 |
8652 |
8747 |
6967 |
7039 |
6965 |
6969 |
6977 |
6977 |
882 |
3725 |
70 |
692 |
6987 |
6987 |
-
|
85405 |
|
Dec
|
6753 |
8264 |
8353 |
6814 |
6887 |
6811 |
6819 |
6821 |
6821 |
928 |
3794 |
62 |
734 |
6764 |
6764 |
-
|
83389 |
|
Control
|
675
|
675
|
675
|
675
|
675
|
675
|
675
|
675
|
675
|
675
|
675
|
675
|
675
|
675
|
675
|
-
|
10125 |
|
Total
|
75735 |
96437 |
97211 |
77852 |
78749 |
77823 |
77896 |
78016 |
78016 |
12722 |
41659 |
1731 |
9280 |
74285 |
74285 |
-
|
951697 |
SPECIAL INVESTIGATIONS (TUMOUR MARKERS) (JAN 2019 TO DEC 2019)
|
Month
|
AFP
|
CEA
|
CA125
|
PSA
|
T3
|
T4
|
TSH
|
TG
|
ATG
|
ATPO
|
BHCG
|
Ca19.9
|
Total
|
|
Jan
|
228
|
374
|
304
|
104
|
475
|
475
|
511
|
123
|
101
|
8
|
109
|
203
|
3015
|
|
Feb
|
220
|
334
|
260
|
98
|
468
|
468
|
493
|
106
|
71
|
5
|
114
|
189
|
2826
|
|
Mar
|
212
|
346
|
370
|
89
|
481
|
481
|
518
|
105
|
70
|
8
|
118
|
206
|
3004
|
|
Apr
|
219
|
328
|
339
|
86
|
423
|
423
|
450
|
85
|
63
|
3
|
107
|
206
|
2732
|
|
May
|
220
|
360
|
373
|
100
|
522
|
522
|
547
|
110
|
82
|
7
|
106
|
220
|
3171
|
|
Jun
|
223
|
340
|
344
|
88
|
554
|
554
|
573
|
92
|
66
|
6
|
108
|
213
|
3164
|
|
Jul
|
217
|
322
|
339
|
85
|
579
|
579
|
602
|
115
|
83
|
9
|
124
|
193
|
3247
|
|
Aug
|
191
|
324
|
298
|
90
|
478
|
487
|
496
|
89
|
58
|
7
|
117
|
187
|
2813
|
|
Sep
|
168
|
310
|
299
|
80
|
491
|
491
|
521
|
81
|
57
|
4
|
109
|
187
|
2799
|
|
Oct
|
161
|
306
|
300
|
81
|
417
|
417
|
436
|
85
|
50
|
9
|
109
|
160
|
2501
|
|
Nov
|
195
|
303
|
289
|
74
|
512
|
512
|
550
|
83
|
70
|
8
|
118
|
162
|
2876
|
|
Dec
|
180
|
321
|
300
|
86
|
502
|
502
|
529
|
86
|
75
|
8
|
109
|
180
|
2878
|
|
Control
|
250
|
350
|
350
|
170
|
350
|
350
|
350
|
170
|
100
|
60
|
150
|
170
|
2820
|
|
Total
|
2684
|
4323
|
1465
|
1232
|
6252
|
6252
|
6576
|
1300
|
946
|
142
|
1498
|
2476
|
37846
|
ಯೋಜನೆಗಳ ಪಟ್ಟಿ
1. Principle Investigatorfor the project “Promoter Methylation of DNA repair genes in ovarian carcinoma: correlation with disease characteristics and prognosis (ICMR).
2. PrincipleInvestigator for the project “The relationship of VEGF polymorphisms with plasma VEGF levels and tumor VEGF expression in epithelial ovarian cancer and their prognostic importance” (ICMR).
3. Principle Investigatorfor the project “ Methylation patterns of gene promoters associated with human ovarian carcinoma” (DBT).
4. Principle Investigator for the project “Investigating galectin based potentiation of malignant ovarian cells within an ascites microenvironment” (RGUHS-IISc).
5. Co-Investigator for the project “Role of hTERT and lengthening of telomere in breast cancer patients.”(RGUHS).
6. Co- Investigatorfor the project titled “Prognostic-Significance of vascular endothelial growth factor(VEGF) polymorphism in cancer Breast” (ICMR).
7. Co-guidefor SRF “ Methylation patterns of gene promoters associated with human ovarian carcinoma” (ICMR).
8. Co-guide for M.ch dissertation entitled “Clinicopathologic, epigenetic features of colorectal cancer” (RGUHS)
9. PhD guide for the project entitled “Role of the Cytoplasmic E-Cadherin Fragment in Ovarian Carcinoma and development of plasma based methylation biomarker panel for early diagnosis and prognosis.” (RGUHS).
10. PhD guide for the project entitled “Role of DNA methylation in predicting response to chemotherapy & understanding signalling pathways involved in ovarian carcinoma.” (RGUHS).
11. PhD guidefor the project entitled “ Aberrant promoter hypermethylation of tumor suppressor genes in endometrial carcinoma- correlation with clinicopathological parameters(RGUHS).
12. Rajiv Gandhi University of Health Sciences, Karnataka Ref. No : RGU:R&D:Res.Wing:2014-15 dated 13/03/2015, Rs 10,00,000/
Title : Role of hTERT expression and lengthening of telomere in breast cancer patients.
13. DST Project Ref. No.SR/FT/LS-94/2010 dated 21-02-2011.under SERC Fast Track Proposals for Young Scientists scheme. Rs 23,78,000/-
Title : A study of expression of cytokines in breast cancer patients.
14. Rajiv Gandhi University of Health Sciences,Karnataka Ref No. RGUHS/R&D/Research Grants/M16/2010-11, dated 23-11-2010, under Medical Faculty.
Title : A study of cytokine polymorphism of tumor necrosis factor in breast cancer patients
CO- Investigator :
15. ICMR Project entitled ”The relationship of VEGF polymorphisms with serum VEGF levels in epithelial ovarian cancer and their prognostic importance.”
ICMR Project Ref. no. 5/13/28/2010-NCD-III(IRIS ID:2010-04560).
16. “Role of the Cytoplasmic E-Cadherin Fragment in Ovarian Carcinoma and development of plasma based methylation biomarker panel for early diagnosis and prognosis.” (RGUHS).
17. “Role of DNA methylation in predicting response to chemotherapy & understanding signalling pathways involved in ovarian carcinoma.” (RGUHS).
18. “ Aberrant promoter hypermethylation of tumor suppressor genes in endometrial carcinoma- correlation with clinicopathological parameters(RGUHS)
ಸಿಬ್ಬಂದಿಗಳ ವಿವರ
Dr.G.RAMESH
Designation : Professor & Head
Qualificatiions : Ph.D
Dr.K.THRIVENI
Designation : Associate Professor
Qualificatiions : Ph.D
Dr. SANDEEP KUMAR
Designation : Associate Professor
Qualificatiions : MBBS, MD
Dr. AKSHATHA L.N
Designation : Assistant Professor
Qualificatiions : MBBS, MD
Mr. VAJRA KUMAR S.P
Designation : Assistant Research Scientist
Qualificatiions : M.Sc
Dr. RACHANA
Designation : Assistant Research Scientist
Qualificatiions : M.Sc, Ph.D
Mr.D. NARASIMHULU
Designation : Chief Laboratatory Technologist
Qualificatiions : B.Sc, MLT
Mr. SHIVASWAMY
Designation : Senior Laboratory Technologist
Qualificatiions : B.Sc, MLT
Mrs. SHIVARATHNAMMA G. S
Designation : Senior Laboratory Technologist
Qualificatiions : B.Sc, MLT
Mr. K.B. LINGARAJU
Designation : Junior Laboratory Technologist
Qualificatiions : B.Sc, MLT
Mrs. KAVITHA S.K
Designation : Junior Laboratory Technologist
Qualificatiions : DMLT
Mrs. SHASHIKALA K.H
Designation : Junior Laboratory Technologist
Qualificatiions : B.Sc, MLT
Mrs. KEERTHY MARY .V
Designation : Junior Laboratory Technologist
Qualificatiions : DMLT
ಸಂಶೋಧನಾ ಪ್ರಕಟಣೆಗಳು
1. Kumar S, Swamy SN, Premalatha CS, Pallavi VR, Gawari R. Aberrant promoter Hypermethylation of RASSF1a and BRCA1 in circulating cell-free tumor DNA serves as a biomarker of ovarian carcinoma. Asian Pacific journal of cancer prevention: APJCP. 2019;20(10):3001.
2. Swamy SN, Kumar S, Devaraj VR, Gawari R. Generation and Characterization of A Carboplatin Resistant Ovarian Cancer Model. Journal of Cancer Science and Clinical Therapeutics.2020;4(3):.
3. Gera S, Kumar S, S, Swamy SN, Bhagat R, Vadaparty A, Gawari R, Bhat R, Dighe RR. Follicle-stimulating hormone is an autocrine regulator of the ovarian cancer metastatic niche through notch signaling. Journal of the Endocrine Society. 2019 Feb;3(2):340-57.
4. Kumar S, Swamy SN, Premalatha CS, Pallavi VR, Gawari R. Down Regulation of RASSF1a, APC and GSTP1 is Associated with Epithelial Ovarian Carcinoma Tumorigenesis. Archives of Clinical and Biomedical Research. 2020;4(4):349-60.
5. L.Krishnamoorthy, G.Ramaswamy, R.Gomathy, V.Kannan, Ramesh G and N.Anantha.“The role of free radical detoxifying systems in the cellular response to radiation therapy in carcinoma of the uterine cervix”. In recent Aspects of cellular and applied radiobiology. Ed.F.H.Schneweis and R.N.Sharma, vol 30, 162 -164,1998.
6. Sunil Chandy, Sadananda Adiga M N, Ramesh G, Girija Ramaswamy, Vijayakumar M, Savithri H S and Lakshmi Krishnamoorthy. “Methylenetetrahydrofolate reductase 677 C®T and 1298 A®C gene polymorphisms and its relation to levels of homocysteine, folate, Vitamin B12 and Vitamin B2 in colorectal cancer”. Austral-Asial J Cancer, 9(2), 91-100, April 2010.
7. Rani James,G. Ramesh, Lakshmi Krishnamoorthy, Triveni K, Vijaylaxmi Deshmane, P P Bapsy, Girija Ramaswamy. “Plasma VEGF as a marker of therapy in breast cancer patients”. Austral Asian J of Cancer 2011; 10(3); 189-95.
8. Rahul Bhagat, Shilpa Chadaga, C.S. Premlatha, G.Ramesh, C. Ramesh, V.R. Pallavi, Lakshmi Krishnamoorthy. “Aberrant promoter methylation of RASSF1A and APC genes in epithelial ovarian carcinoma development”. Cell Oncol (2012) 35: 473-479.
9. Rahul Bhagat, C. S. Premalata, V. Shilpa, V. R. Pallavi, G. Ramesh, C. R. Vijay & Lakshmi Krishnamoorthy “Altered expression of β-catenin, Ecadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma”. Tumor Biol. DOI 10.1007/s13277-013-0797-9. April -2013.
10. Rahul Bhagat, Sandeep K, V. Shilpa , C. S. Premalata, , V. R. Pallavi, G. Rameshand Lashmi K. “Epigenetic alterations of p16 and Retinoic Acid receptor beta genes in the development of epithelial ovarian carcinoma” Tumor Biology. DOI 10.10007/s13277-014-213-1 (2014).
11. Shilpa V, Rahul B, C S Premalatha, Pallavi V R, G.Rameshand Lakshmi K “BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma- An Indian Study. Tumor Biology 2014; 35:4277-424. DOI:10.1007/s13277-013-1558-5.
12. Bhaskari Janardhan; Shilpa V; Rahul B; Premalatha C.S.; Pallavi V.R.; Ramesh G; Lakshmi Krishnamoorthy, 'Investigating impact of Vascular Endothelial Growth Factor polymorphisms in epithelial ovarian cancers: A study in the Indian population', Accepted for Publication in Plos One.
13. Thriveni K,Raju A, Kumar RV, Krishnamurthy S, Chaluvarayaswamy R. Patterns of Relative Telomere Length in Associated with hTERT Gene Expressionin the Tissue of Breast Cancer Patients Clin Breast Cancer.2019;19:27-34.
14. Thriveni K,Raju A, Ramaswamy G, Krishnamurthy S, Kumar RV. Tumor necrosis factor: An inflammatory microenvironment marker in primary breast cancer patients. Int J Mol Immuno Oncol 2018;3:24-27.
15. Thriveni K,Raju A, Ramaswamy G, Krishnamurthy S, Kumar RV. An Analysis of Polymorphism Lymphotoxin alpha +252 A>G in South Indian Breast Cancer Patients. International Journal of Hematology and Oncology 2017;27: 229-236.
16. Thriveni K, Raju A. Integrity of genomic DNA isolated from heparin treated human leukocytes by a modified protocol. IOSR Journal of Dental and Medical Sciences 2016; 15:97-100.
17.James R, Ramesh G, Krishnamoorthy L, Thriveni K, Deshmane V, Bapsy PP, Ramaswamy G.Plasma VEGF as a Marker of Therapy in Breast Cancer Patients. Austral-Asian Journal of Cancer 2011;10:189-95.
18. Thriveni K, James R, Krishnamoorthy L, Deshmane V, Bapsy PP, Ramaswamy G. Upregulation of telomerase activity by HER-2/neu and its significance in breast cancer. International Journal of Haematology and Oncology.2010;3:141-147.
19. Thriveni K, James R, Krishnamoorthy L, Deshmane V, Bapsy PP, Ramaswamy G. Serum transaminases ratio in breast cancer patients. Austral Asian Journal of Cancer.2009;8:199-20.
20. Girija Ramaswamy, Vasanthi Rao, Lakshmi Krishnamoorthy, Ramesh, Gomathy R and Renuka Devi D. “Serum level of bone alkaline phosphatase in breast and prostate cancers with bone metastasis”. Ind. J. Clin Biochemistry. 15(2), 110-113, (2000)
21. Rani James, Ramesh, Lakshmi Krishnamoorthy, Rahul Bhagat, Shilpa Chadaga, Vijayalaxmi Deshmane, Girija Ramaswamy. “Prevalence of +405G>C,−1154G>A Vascular Endothelial Growth Factor Polymorphism in Breast Cancer”. Ind J Clin Biochem. 2013. DOI 10.1007/s12291-013-0307-2, Feb-2013.
22. Shilpa V, Rahul B, C S Premalatha, Pallavi V R, Rameshand Lakshmi K. “The relationship between romoter methylation and tissue expression of MGMT gene in ovarian cancer. Indian Journal of Medical Research(2014).
23. Ramesh, Shalini N. Swamy, S. Sandeep Kumar, C. S. Premalata, V. R. Pallavi. ”Aberrant Promoter Hypermethylation of Death Associated Protein Kinase (DAPK) in Epithelial Ovarian Carcinoma”. Journal of Evidence based Medicine and Healthcare, 2015.
24. Ramesh, S. Sandeep Kumar, Shalini N. Swamy, C. S. Premalata, V. R. Pallavi. ”A Study on the Aberrant Promoter Hypermethylation of RAR-β Gene in the Plasma of Epithelial Ovarian Carcinoma Patients”. Journal of Evidence based Medicine and Healthcare, 2015.
25. Ramesh, S. Sandeep Kumar, Shalini N. Swamy, C. S. Premalata, V. R. Pallavi. ”The Aberrant Promoter Hypermethylation Pattern of the Anti-Angiogenic TSP1 Gene in Epithelial Ovarian Carcinoma: An Indian Study”. Journal of Evidence based Medicine and Healthcare, 2015.
26. Rani James, Rahul Bhagat, Shilpa Chadaga, Thriveni K, Lakshmi Krishnamoorthy, G Ramesh,Girija Ramaswamy. “Association of vascular endothelial growth factor (VEGF) single nucleotide polymorphisms(SNPs) and prognosis of Breast cancer patients. Accepted for Publication in Indian Journal of Cancer.
27. Sandeep Kumar, Noopur Nelson Manisha Roy Govardhan Khaleel Pallavi Ramesh. IS LOCALLY ADVANCED CANCER CERVIX ASSOCIATED WITH HYPOALBUMINEMIAAND INCREASED GRANULOCYTE AND LYMPHOCYTE RATIO? Volume-8 | Issue-3 | March-2019 | PRINT ISSN No 2277 – 8179.
28. Kumar S, Roy M, Nelson N, Govardhan G, Khaleel K, R. P, Ramesh. Pre-treatment de-ritis ratio as a marker for cervical cancer: a study at regional cancer centre. Int J Med Res Rev [Internet]. 2019Jun.30 [cited 2020Nov.27];7(3):162-9.
29. Kumar S, Swamy SN, Premalatha CS, Pallavi VR, Gawari R. Aberrant promoter Hypermethylation of RASSF1a and BRCA1 in circulating cell-free tumor DNA serves as a biomarker of ovarian carcinoma. Asian Pacific journal of cancer prevention: APJCP. 2019;20(10):3001.
30. Gera S, Kumar S, S, Swamy SN, Bhagat R, Vadaparty A, Gawari R, Bhat R, Dighe RR. Follicle-stimulating hormone is an autocrine regulator of the ovarian cancer metastatic niche through notch signaling. Journal of the Endocrine Society. 2019 Feb;3(2):340-57.
31. Sandeep Kumar, Noopur Nelson Manisha Roy Govardhan Khaleel Pallavi Ramesh. Is Locally Advanced Cancer Cervix Associated With Hypoalbuminemiaand Increased Granulocyte And Lymphocyte Ratio? Volume-8 | Issue-3 | March-2019 | PRINT ISSN No 2277 – 8179.
32. Kumar S, Roy M, Nelson N, Govardhan G, Khaleel K, R. P, G. Ramesh. Pre-treatment de-ritis ratio as a marker for cervical cancer: a study at regional cancer centre. Int J Med Res Rev [Internet]. 2019Jun.30 [cited 2020Nov.27];7(3):162-9.
33. Thriveni K,Raju A, Kumar RV, Krishnamurthy S, Chaluvarayaswamy R. Patterns of Relative Telomere Length in Associated with hTERT Gene Expressionin the Tissue of Breast Cancer Patients Clin Breast Cancer.2019;19:27-34.
34. Thriveni K,Raju A, Ramaswamy G, Krishnamurthy S, Kumar RV. Tumor necrosis factor: An inflammatory microenvironment marker in primary breast cancer patients. Int J Mol Immuno Oncol 2018;3:24-27.
35. Thriveni K,Raju A, Ramaswamy G, Krishnamurthy S, Impact of Gene Polymorphism of TNFα rs 1800629 and TNFβ rs 909253 on Plasma Levels of South-Indian Breast Cancer Patients. Ind J Cancer.2018;55:179-183.
36. Sandeep Kumar, Noopur Nelson Manisha Roy Govardhan Khaleel Pallavi Ramesh. Is Locally Advanced Cancer Cervix Associated With Hypoalbuminemiaand Increased Granulocyte And Lymphocyte Ratio? Volume-8 | Issue-3 | March-2019 | PRINT ISSN No 2277 – 8179.
37. Kumar S, Roy M, Nelson N, Govardhan G, Khaleel K, R. P, G. Ramesh. Pre-treatment de-ritis ratio as a marker for cervical cancer: a study at regional cancer centre. Int J Med Res Rev [Internet]. 2019Jun.30 [cited 2020Nov.27];7(3):162-9.
38. Thriveni K,Raju A, Ramaswamy G, Krishnamurthy S, Impact of Gene Polymorphism of TNFα rs 1800629 and TNFβ rs 909253 on Plasma Levels of South-Indian Breast Cancer Patients. Ind J Cancer.2018;55:179-183.
39. Thriveni K, Deshmane V, Ramaswamy G, Krishnamoorthy L. Diagnostic Significance of CA15-3 with combination of HER-2/neu values at 85th percentiles in breast cancer. Ind J Clin Biochem. 2013; 28:136–140.
40. James R, Thriveni K,Krishnamoorthy L , Deshmane V , Bapsy PP, Ramaswamy G. Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer. Indian J Med Res. 2011; 133: 70-75.
41. James R, Thriveni K, Bapsy PP, Krishnamoorthy L, Mukherjee G , Deshmane V , Ramaswamy G. Evaluation of immunohistochemistry (IHC) and enzyme linked immunosorbent assay (ELISA) for HER-2/neu expression in breast carcinoma. Ind.J.Clin Biochemistry 2008; 23: 345-351.
42. Thriveni Kand Girija Ramaswamy. “A study of serum Her-2/neu expression in cancer breast along with other prognostic factors like CEA, CA15-3 and tissue telomerase activity”. D. Thesis, Rajiv Gandhi University of Health Sciences, Karnataka. 2008.
43. Thriveni K, Krishnamoorthy L, Ramaswamy G. Correlation study of carcino embryonic antigen and cancer antigen 15.3 in breast cancer patients. Ind.J.Clin Biochemistry 2007; 22: 57-60.
44. Thriveni K, Krishnamoorthy L, Ramaswamy G. Clinical utility of serum human epidermal receptor-2/neu in breast cancer patients. Indian J Med Res 2007; 125: 137-142.
45. Sandeep Kumar, Noopur Nelson Manisha Roy Govardhan Khaleel Pallavi Ramesh. Is Locally Advanced Cancer Cervix Associated With Hypoalbuminemiaand Increased Granulocyte And Lymphocyte Ratio? Volume-8 | Issue-3 | March-2019 | PRINT ISSN No 2277 – 8179.
46. Kumar S, Roy M, Nelson N, Govardhan G, Khaleel K, R. P, G. Ramesh. Pre-treatment de-ritis ratio as a marker for cervical cancer: a study at regional cancer centre. Int J Med Res Rev [Internet]. 2019Jun.30 [cited 2020Nov.27];7(3):162-9.
47. Kharb, S. Kumarand Z.S. Kundu, 2013. Implications of Raised Folate and Lowered Vitamin B12in Osteosarcoma. American Journal of Biochemistry and Molecular Biology, 3: 182-187.
48. Kharb S, Kumar S, Kundu Z S. Homocysteine, a biomarker of osteosarcoma. J Can Res Ther 2015;11:51-3
49. Shwetha Nagaraj, Akshatha Lalesh Naik, Pratibha K ,Vinay Kumar K. Prostate Specific Antigen in Women with PCOS and Its Correlation with Total Testosterone.International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 15, Number 2 (2019) pp. 87-95.
50. Akshatha LN, Srikrishna R, Kumar S V, Shenoy M T, Mansrekar P A, Hepatic and renal dysfunctions in a malaria endemic region: falciparum malaria vs vivax malaria. Int J Clin Biochem Res 2017;4(4):324-328.
51. L N Akahatha,Shenoy MT, Yadav C, M S R, Kamath N. Bronze diabetes. J Clin Diagn Res. 2015 Apr;9(4):BD01-2. doi: 10.7860/JCDR/2015/11515.5799. Epub 2015 Apr 1. PMID: 26023548; PMCID: PMC4437060.
52. Shenoy MT, D'Souza B, Akshatha LN, D'Souza V, Rajan MG. Spontaneous Tumor Lysis Syndrome in an Infant: A Case Report. Indian J Clin Biochem. 2015 Jul;30(3):360-2. doi: 10.1007/s12291-014-0472-y. Epub 2015 Feb 14. PMID: 26089626; PMCID: PMC4469048.
53. L N Akshatha, M S R, Shenoy MT, P SR, B P. Lead poisoning mimicking acute porphyria! J Clin Diagn Res. 2014 Dec;8(12):CD01-2. doi: 10.7860/JCDR/2014/10597.5315. Epub 2014 Dec 5. PMID: 25653942; PMCID: PMC4316248.
54. Srikrishna R , Akshatha L.N., Dr. Virupaksha L, Vinay Kumar K. Study of HS-CRP, Insulin Resistance and Dyslipidemia as Predictive Markers in PreHpertension”. International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 13, Number 4 (2017) pp. 413-421.
55. Naik AL, Rajan MG, Manjrekar PA, et al. Effect of DOTS Treatment on Vitamin D Levels in Pulmonary Tuberculosis. Journal of Clinical and Diagnostic Research : JCDR. 2017 Apr;11(4):BC18-BC22. DOI: 10.7860/jcdr/2017/24501.9759.
56. Shenoy MT, D'Souza B, Akshatha LN, D'Souza V, Rajan MG. Spontaneous Tumor Lysis Syndrome in an Infant: A Case Report. Indian Journal of Clinical Biochemistry : IJCB. 2015 Jul;30(3):360-362. DOI: 10.1007/s12291-014-0472-y.
57. Akshatha, L.N. & Shenoy, Mamatha & D'Souza, Benedicta & D'Souza, V. & Prabhu, A.K. & Hegde, Anupama & Suresh, Pooja. (2014). Elevated ferritin level in a patient with autoimmune haemolytic anaemia. Biomedicine (India). 34. 412-414.
58. Kuthethur, S., Kumarchandra, R., LN Akshatha.,Gopal, M., Salins, J., & Poojari, P. (2014). Evaluation of serum uric acid /inorganic phosphate ratio in prostate disorders and healthy controls. International Journal of Biomedical and Advance Research, 5(7), 345–347. https://doi.org/10.7439/ijbar.v5i7.807
59. Kumarchandra, Reshma & Akshatha, L.N.(2014). Serum uric acid - Phosphate ratio as a differential diagnostic marker of prostate disorders. International Journal of Pharma and Bio Sciences. 5. B196-B200.
60. Shenoy, Mamatha & D'Souza, Benedicta & Akshatha, L.N.& Puneeth, A. & M S, Rukmini & Hegde, Anupama & D'Souza, V.. (2014). Elevated d-dimer level in acute myeloid leukemia. Biomedicine (India). 34. 267-268.
61. Ramarajan Madan, Naik Akshatha, Hegde Anupama , A Puneeth , Shenoy Mamatha, P Shaheena, Manjrekar Poornima. (2016). Effects of iron status on pulmonary tuberculosis in response to directly observed treatment short course (DOTS). Biomedicine. 36. 015-021.
62. VK Kumar, Shubha , Akshatha LN, Suhas HG ,Sathyajith Thopachiche. Comparison of One-step technique and Two-step technique for Making Impressions using Polyvinylsiloxane for FPD. Journal of Advanced Medical and Dental Sciences Research. |Vol. 6|Issue 4| April 2018. ):55-58.
63. Kuruvanthe S. Rachana,Mallahalli S. Manu, Gopal M. Advirao. Insulin-induced up regulation of lipoprotein lipase in Schwann cells during diabetic peripheral neuropathy. Diabetes and Metabolic syndrome: Clinical Research and Reviews, 2018; DOI:10.1016/j.dsx.2018.03.017.
64. Kuruvanthe S. Rachana, Mallahalli S. Manu, Gopal M. Advirao. Role of insulin in the expression of PMP22, a myelin protein during diabetic peripheral neuropathy. IOSR Journal of Biotechnology and Biochemistry, 2017; 3(6), 50-55.
65. Kuruvanthe S. Rachana, Mallahalli S. Manuand Gopal M. Advirao. Insulin influenced expression of myelin proteins in diabetic peripheral neuropathy. Neuroscience Letters, 2016; 629:110-115.
66. Mallahalli S. Manu, Kuruvanthe S. Rachana, and Gopal M. Advirao. Altered expression of IRS2 and GRB2 in demyelination of peripheral neurons: Implications in diabetic neuropathy. Neuropeptides, 2017; 62:71-19.
67. Mallahalli S. Manu, Kuruvanthe S. Rachana, and Gopal M. Advirao. Insulin inhibits the JNK mediated cell death via up regulation of AKT expression in Schwann cells grown in hyperglycemia. Frontiers in Biology, 2018; DOI:10.1007/s11515-018-1492-4.#
68. Mallahalli S. Manu, Kuruvanthe S. Rachana, and Gopal M. Advirao. Insulin elevates the down regulated OCT-6 transcription factor in diabetic peripheral neuropathy. Genes and Diseases, 2017; DOI:10.1016/j.gendis.2017.12.007.
Awards Obtained
69. Award for Research Publications for the year 2018-19 by Vision Group on Science and Technology Govt, of Karnataka
ಕರ್ನಾಟಕ ಸರ್ಕಾರದ ಅಧಿಕೃತ ಜಾಲತಾಣ
